Drug Trial Radar · NCT05443984
JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis
Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jan 17, 2022
Primary completion
Jan 5, 2023
Study completion Jan 5, 2023
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis
Conditions
- Erosive Esophagitis
Interventions
JP-1366 20mgDrug
1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)
Esomeprazole 40mgDrug
1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The cumulative healing rate of mucosal break at 8-week after the investigational product administration (%)Time frame: Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center and 26 hospitals
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.